FindTrial
Sign In

Vutrisiran

DRUG4 trials

Sponsors

Alnylam Pharmaceuticals

Conditions

Amyloidosis, HereditaryHereditary Transthyretin-Mediated Amyloidosis With PolyneuropathyTransthyretin AmyloidosisTransthyretin Amyloidosis (ATTR) With CardiomyopathyhATTR-PN

Phase 3

HELIOS-A: A Study of Vutrisiran (ALN-TTRSC02) in Patients With Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis)
CompletedNCT03759379
Alnylam PharmaceuticalsAmyloidosis, Hereditary, Transthyretin Amyloidosis
Start: 2019-02-14End: 2025-11-05Updated: 2026-01-12
HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
Active, not recruitingNCT04153149
Alnylam PharmaceuticalsTransthyretin Amyloidosis (ATTR) With Cardiomyopathy
Start: 2019-11-26End: 2026-12-02Updated: 2026-01-12
A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
Enrolling by invitationNCT06679946
Alnylam PharmaceuticalsTransthyretin Amyloidosis (ATTR) With Cardiomyopathy
Start: 2024-12-03End: 2028-03-31Target: 700Updated: 2026-02-20
TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy
RecruitingNCT07223203
Alnylam PharmaceuticalshATTR-PN, Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy
Start: 2026-02-03End: 2031-06-12Target: 125Updated: 2026-09-15

Related Papers

Effect of Vutrisiran According to Baseline Tafamidis Use in Transthyretin Amyloidosis With Cardiomyopathy: Insights From HELIOS-B.
2026-08-30
Gene Silencer Therapy in Transthyretin Amyloid Cardiomyopathy: A Meta-Analysis of Outcomes Trials.
2026-08-30
Right Ventricular Function, Clinical Outcomes, and Effect of Vutrisiran in Transthyretin Amyloidosis With Cardiomyopathy
JAMA Cardiology2026-08-26
Long-term efficacy and safety of vutrisiran in hereditary transthyretin amyloidosis with polyneuropathy: final analysis of the HELIOS-A randomized treatment extension
Figshare2026-07-27
Long-term efficacy and safety of vutrisiran in hereditary transthyretin amyloidosis with polyneuropathy: final analysis of the HELIOS-A randomized treatment extension
Figshare2026-06-15
Long-term efficacy and safety of vutrisiran in hereditary transthyretin amyloidosis with polyneuropathy: final analysis of the HELIOS-A randomized treatment extension
Figshare2026-06-15
Long-term efficacy and safety of vutrisiran in hereditary transthyretin amyloidosis with polyneuropathy: final analysis of the HELIOS-A randomized treatment extension
Amyloid2026-06-15
Vutrisiran-Mediated Knockdown of Transthyretin in Patients with ATTR Amyloidosis.
2026-05-27
Efficacy and Safety of Vutrisiran in Patients with Hereditary Transthyretin-mediated Amyloidosis with Polyneuropathy: Analysis of the East Asian Subpopulation from HELIOS-A.
2026-03-04
Abstract 4362795: Vutrisiran Improved Outcomes Versus Placebo in Patients with Transthyretin Amyloidosis with Cardiomyopathy and Severe Chronic Kidney Disease: Post Hoc Analysis of HELIOS-B
Circulation2025-11-03
Timing of Mortality Benefit in Outcomes Trials in Transthyretin Amyloidosis.
2025-09-251 citations
Effects of vutrisiran on cardiac structure and function in patients with transthyretin amyloidosis with cardiomyopathy: secondary outcomes of the HELIOS-B trial.
2025-08-064 citations
Impact of Vutrisiran on Cardiac Biomarkers in Patients With Transthyretin Amyloidosis With Cardiomyopathy From HELIOS-B
Journal of the American College of Cardiology2025-08-014 citations
Vutrisiran Improves Survival and Reduces Cardiovascular Events in ATTR Amyloid Cardiomyopathy
Journal of the American College of Cardiology2025-05-0114 citations
Impact of Heart Failure Severity on Vutrisiran Efficacy in Transthyretin Amyloidosis With Cardiomyopathy
Journal of the American College of Cardiology2025-03-176 citations
HELIOS-A: 18-month randomized treatment extension analysis of vutrisiran in patients with hereditary transthyretin amyloidosis with polyneuropathy
2025-01-01
Outpatient Worsening Heart Failure in Patients With Transthyretin Amyloidosis With Cardiomyopathy in the HELIOS-B Trial
Journal of the American College of Cardiology2024-11-1820 citations
Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy
New England Journal of Medicine2024-08-30273 citations
Impact of Baseline Polyneuropathy Severity on Vutrisiran Treatment Response in the Phase 3 HELIOS-A Study (P2-11.015)
Neurology2024-04-09
Impact of Baseline Neuropathy Severity on Vutrisiran Treatment Response in the Phase 3 HELIOS-A Study.
2024-03-211 citations

8 more papers not shown